Literature DB >> 30216847

Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 'Best of' and 24954 'larynx preservation' study.

Christian Simon1, Carmela Caballero2, Vincent Gregoire3, Dietmar Thurnher4, Petri Koivunen5, Philippe Ceruse6, Giuseppe Spriano7, Piero Nicolai8, Lisa Licitra9, Jean-Pascal Machiels10, Marc Hamoir11, Guy Andry12, Hisham Mehanna13, Keith D Hunter14, Andreas Dietz15, C René Leemans16.   

Abstract

Quality improvement of care for patients with head and neck cancer remains a constant objective for the multidisciplinary team of physicians managing these patients. The purpose of quality assurance (QA) for head and neck surgical oncology and surgical trials however differs. While QA for the general head and neck patient aims to improve global outcome through structural changes of health-care systems, QA for surgical trials pursues the goal to help providing meaningful results from a clinical trial through the definition of structure, process and outcome measures within the trial. Establishing a QA program for surgical trials is challenging largely due to the variation in the execution of surgical techniques. Within this article, we describe the surgical QA program, which was developed for the phase III European Organisation for Research and Treatment of Cancer (EORTC) 1420 study, a trial assessing swallowing function after transoral surgery compared with radiation therapy. We propose based on our experience to further develop surgical QA for surgical clinical trials by introducing two separate components, one adaptable and one non-adaptable. The adaptable is tailored to the scientific question and specific procedure; the non-adaptable consists of minimal structural requirements of the clinical unit to participate in surgical trials at EORTC as well as guidelines and incentives for protocol adherence based on our experience in EORTC 24954. Finally, we strongly believe that surgical QA designed for clinical trials may serve as a basis for the development of QA surgical guidelines in clinical practice.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trials; EORTC; Head and neck cancer; Quality assurance; Surgery

Mesh:

Year:  2018        PMID: 30216847     DOI: 10.1016/j.ejca.2018.07.140

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer.

Authors:  Kristen Moloney; Monika Janda; Michael Frumovitz; Mario Leitao; Nadeem R Abu-Rustum; Emma Rossi; James L Nicklin; Marie Plante; Fabrice R Lecuru; Alessandro Buda; Andrea Mariani; Yee Leung; Sarah Elizabeth Ferguson; Rene Pareja; Rainer Kimmig; Pearl Shuang Ye Tong; Orla McNally; Naven Chetty; Kaijiang Liu; Ken Jaaback; Julio Lau; Soon Yau Joseph Ng; Henrik Falconer; Jan Persson; Russell Land; Fabio Martinelli; Andrea Garrett; Alon Altman; Adam Pendlebury; David Cibula; Roberto Altamirano; Donal Brennan; Thomas Edward Ind; Cornelis De Kroon; Ka Yu Tse; George Hanna; Andreas Obermair
Journal:  Int J Gynecol Cancer       Date:  2021-03-04       Impact factor: 4.661

2.  Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the "Best of" Trial.

Authors:  Jean-Jacques Stelmes; Vincent Gregoire; Vincent Vander Poorten; Wojciech Golusiñski; Mateusz Szewczyk; Terry Jones; Mohssen Ansarin; Martina A Broglie; Roland Giger; Jens Peter Klussmann; Mererid Evans; Jean Bourhis; C René Leemans; Giuseppe Spriano; Andreas Dietz; Keith Hunter; Frank Zimmermann; Ingeborg Tinhofer; Joanne M Patterson; Silvana Quaglini; Anne-Sophie Govaerts; Catherine Fortpied; Christian Simon
Journal:  Front Oncol       Date:  2019-10-22       Impact factor: 6.244

Review 3.  Value and Quality of Care in Head and Neck Oncology.

Authors:  Robert P Takes; Gyorgy B Halmos; John A Ridge; Paolo Bossi; Matthias A W Merkx; Alessandra Rinaldo; Alvaro Sanabria; Ludi E Smeele; Antti A Mäkitie; Alfio Ferlito
Journal:  Curr Oncol Rep       Date:  2020-07-10       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.